Published on Fri Sep 17 2021

Developing selective FPR2 agonists can be a potential approach to treat moderate to severe asthma.

Visaga, S. A., Kalonia, H., Verma, V., Sinha, S., Singh, S. K., Upadhyay, S., Sahdev, S., Pansari, A., Kumar, R., Bandgar, M., Karanjule, N., Shirumalla, R. K., Morishita, K., Tandon, R.

Formyl peptide receptor (FPR) family members have been reported to play important role in the resolution of inflammation. FPR2/FPR1 dual agonists are reported in the public domain for their anti-inflammatory properties. None of these molecules have been successful as a therapy yet.

1
0
1
Abstract

Formyl peptide receptor (FPR) family members have been reported to play important role in the resolution of inflammation. A few FPR2/FPR1 dual agonists are reported in the public domain for their anti-inflammatory properties. None of these molecules, however, have been successful as a therapy yet. Recent reports bring forward the ambiguous role of FPR1 in inflammation. These include both positive and negative outcomes. We, therefore, aimed to develop selective FPR2 agonists and evaluated their potential in mitigating the non-resolving inflammation in mouse models of moderate to severe asthma. Extensive structure-activity-relationship (SAR) studies were conducted on the imidazole and benzimidazole chemotype series to identify potent and selective FPR2 agonists. A few molecules were shortlisted based on their in vitro profile and absorption, distribution, metabolism and excretion (ADME) properties and were further evaluated in mouse models of asthma. We report herewith identification of 3 RCI compounds with low nanomolar potency for FPR2 agonism and >10,000 fold selectivity over FPR1 in Ca2+ release assay. These molecules also showed potency in other in vitro assays and potent efficacy in three distinct animal models of asthma. Our data suggest that FPR2 agonism can be a potential therapeutic approach to treat asthma. Our findings also propose that FPR1 can be spared to achieve the desired pharmacological activity.